Sigma Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Sigma Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-60,000	Closed	-$1.18M	–	224
2013 Q4	$1.18M	Sell	60,000 -115,000	-66%	-$3.07M	0.07%	138
2013 Q3	$7.93M	Buy	175,000 +65,000	+59%	+$2.12M	0.33%	89
2013 Q2	$2.62M	Buy	+110,000	New	+$1.75M	0.12%	161

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sigma Capital Management's STML Position: Q1 2014 in Review

Sigma Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 60,000 shares — an estimated $1.18M sold.

Sigma Capital Management first reported a position in STML in Q2 2013 and held it in 3 quarters. The position peaked at $7.93M in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

Sigma Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
Sigma Capital Management sold 60,000 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $1.18M.
Sigma Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
Sigma Capital Management's Stemline Therapeutics, Inc. position peaked at $7.93M in Q3 2013.
61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Sigma Capital Management's 13F filing for Q1 2014, filed 15 May 2014.